Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 16/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 16/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723998 | 1.00 | PDE3B (1.00) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| Methylamine SCHEMBL10474969 | 0.97 | PDE3B (0.95) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| Dimethylamine SCHEMBL10475180 | 0.97 | PDE3B (0.95) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL5678932 | 0.88 | PDE3B (0.77) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL5678929 | 0.88 | PDE3B (0.77) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL11180354 | 0.87 | PDE3B (0.77) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL11165047 | 0.87 | PDE3B (0.77) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL11160996 | 0.87 | PDE3B (0.78) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL10472650 | 0.87 | PDE3B (0.76) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL10472264 | 0.86 | PDE3B (0.75) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076398-B1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF) | TENAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250064799-A1 | ORAL FORMULATIONS OF LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION | TENAX THERAPEUTICS, INC. (US) | 2025-02-27 | — | — | US | claimed |
| US-20250025460-A1 | USE OF A COMBINATION OF LEVOSIMENDAN AND AN SGLT-2 INHIBITOR TO TREAT HEART FAILURE | TENAX THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | US | claimed |
| EP-4456897-A1 | ORAL FORMULATIONS OF LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION | Tenax Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | claimed |
| US-20240269134-A1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | TENAX THERAPEUTICS, INC. (US) | 2024-08-15 | — | — | US | claimed |
| US-11969424-B2 | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) | TENAX THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | claimed |
| US-11701355-B2 | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) | TENAX THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | claimed |
| WO-2023130028-A1 | ORAL FORMULATIONS OF LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION | TENAX THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | claimed |
| US-20230107461-A1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | TENAX THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | US | claimed |
| US-11607412-B2 | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) | TENAX THERAPEUTICS INC. (US) | 2023-03-21 | — | — | US | claimed |
| US-20220370445-A1 | METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE | ORION CORPORATION (FI) | 2022-11-24 | — | — | US | claimed |
| EP-4076398-A1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF) | Tenax Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| EP-3993773-A1 | METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE | Orion Corporation (FI) | 2022-05-11 | — | — | EP | claimed |
| US-20220096470-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION OF LEVOSIMENDAN | TENAX THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | US | claimed |
| EP-1581227-B1 | A METHOD FOR TREATING RENAL FAILURE | ORION CORP (FI) | 2007-02-28 | — | — | EP | claimed |
| US-20060166994-A1 | Method for treating renal failure | ORION CORPORATION (FI) | 2006-07-27 | — | — | US | claimed |
| US-7045147-B1 | Controlled release peroral compositions of levosimendan | ORION CORPORATION (FI) | 2006-05-16 | — | — | US | claimed |
| EP-1087769-B1 | USE OF A PYRIDAZINONE DERIVATIVE AS CALCIUM SENSITIZER | ORION CORP (FI) | 2004-03-10 | — | — | EP | claimed |
| US-RE38102-E1 | Use of a pyridazinone derivative | ORION CORPORATION (FI) | 2003-04-29 | — | — | US | claimed |
| US-12616694-B2 | Pharmaceutical compositions for subcutaneous administration of levosimendan | TENAX THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4076398-B1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF) | TENAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| CN-119745787-A | Transdermal gel preparation and preparation method thereof | 浙江仙琚制药股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20250064799-A1 | ORAL FORMULATIONS OF LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION | TENAX THERAPEUTICS, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250025460-A1 | USE OF A COMBINATION OF LEVOSIMENDAN AND AN SGLT-2 INHIBITOR TO TREAT HEART FAILURE | TENAX THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | US | disclosed |
| US-20250025460-A1 | USE OF A COMBINATION OF LEVOSIMENDAN AND AN SGLT-2 INHIBITOR TO TREAT HEART FAILURE | TENAX THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4456897-A1 | ORAL FORMULATIONS OF LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION | Tenax Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240269134-A1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | TENAX THERAPEUTICS, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-11969424-B2 | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) | TENAX THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-11701355-B2 | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) | TENAX THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2023130028-A1 | ORAL FORMULATIONS OF LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION | TENAX THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230107461-A1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | TENAX THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-11607412-B2 | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) | TENAX THERAPEUTICS INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20220370445-A1 | METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE | ORION CORPORATION (FI) | 2022-11-24 | — | — | US | disclosed |
| US-20220370445-A1 | METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE | ORION CORPORATION (FI) | 2022-11-24 | — | — | US | disclosed |
| EP-4076398-A1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF) | Tenax Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-3993773-A1 | METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE | Orion Corporation (FI) | 2022-05-11 | — | — | EP | disclosed |
| US-20220096470-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION OF LEVOSIMENDAN | TENAX THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220071995-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | THE BROAD INSTITUTE, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11213524-B2 | Pharmaceutical compositions for subcutaneous administration of levosimendan | TENAX THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11207320-B2 | Compositions and methods for cancer expressing PDE3A or SLFN12 | THE BROAD INSTITUTE, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210393625-A1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | TENAX THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3411037-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | Bayer Pharma AG (DE) | 2021-10-20 | — | — | EP | disclosed |
| US-20210236504-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-05 | — | — | US | disclosed |
| US-20210177840-A1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | TENAX THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10966986-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-06 | — | — | US | disclosed |
| WO-2021001601-A1 | METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE | ORION CORPORATION (FI) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021001601-A1 | METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE | ORION CORPORATION (FI) | 2021-01-07 | — | — | WO | disclosed |
| US-20200330463-A1 | Pharmaceutical Compositions for Subcutaneous Administration of Levosimendan | TENAX THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| EP-2970145-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BROAD INST INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3206690-A1 | LEVOSIMENDAN FOR USE IN THE TREATMENT OF MOTOR NEURON DISEASES (E.G. ALS) | Orion Corporation (FI) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017134231-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017027854-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | THE BROAD INSTITUTE, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016059287-A1 | LEVOSIMENDAN FOR USE IN THE TREATMENT OF MOTOR NEURON DISEASES (E.G. ALS) | ORION CORPORATION (FI) | 2016-04-21 | — | — | WO | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2014164704-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-2185141-A1 | A COMBINATION TREATMENT | ORION CORPORATION (FI) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009027577-A1 | A COMBINATION TREATMENT | ORION CORPORATION (FI) | 2009-03-05 | — | — | WO | disclosed |
| WO-2008134602-A1 | LEVOSIMENDAN DOSAGE REGIMEN | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080077025-A1 | METHODS FOR DETERMINING HOW TO TREAT CONGESTIVE HEART FAILURE | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080070917-A1 | METHODS FOR ADMINISTERING LEVOSIMENDAN | ABBOTT LABORATORIES | 2008-03-20 | — | — | US | disclosed |
| EP-1858518-A1 | A COMBINATION TREATMENT FOR ENHANCING DIURESIS | ORION CORPORATION (FI) | 2007-11-28 | — | — | EP | disclosed |
| EP-1848434-A2 | A METHOD FOR TREATING HEART FAILURE | ORION CORPORATION (FI) | 2007-10-31 | — | — | EP | disclosed |
| US-20070032557-A1 | Method for administering levosimendan | KIVIKKO MATTI | 2007-02-08 | — | — | US | disclosed |
| WO-2007008907-A2 | METHODS FOR DETERMINING HOW TO TREAT CONGESTIVE HEART FAILURE | ABBOTT LABORATORIES (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070010518-A1 | Method for administering levosimendan | ORION CORPORATION (FI) | 2007-01-11 | — | — | US | disclosed |
| EP-1401450-B1 | USE OF A PYRIDAZINONE DERIVATIVE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE | ORION CORP (FI) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006097570-A1 | A COMBINATION TREATMENT FOR ENHANCING DIURESIS | ORION CORPORATION (FI) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006087420-A2 | A METHOD FOR TREATING HEART FAILURE | ORION CORPORATION (FI) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006087419-A2 | A METHOD FOR ADMINISTERING LEVOSIMENDAN | ORION CORPORATION (FI) | 2006-08-24 | — | — | WO | disclosed |
| EP-1581227-A1 | A METHOD FOR TREATING RENAL FAILURE | ORION CORPORATION (FI) | 2005-10-05 | — | — | EP | disclosed |
| US-20040180895-A1 | Use of a pyridazinone derivative | ORION CORPORATION (FI) | 2004-09-16 | — | — | US | disclosed |
| WO-2004060375-A1 | A METHOD FOR TREATING RENAL FAILURE | ORION CORPORATION (FI) | 2004-07-22 | — | — | WO | disclosed |
| EP-1401450-A1 | NEW USE OF A PYRIDAZINONE DERIVATIVE | ORION CORPORATION (FI) | 2004-03-31 | — | — | EP | disclosed |
| EP-1087769-B1 | USE OF A PYRIDAZINONE DERIVATIVE AS CALCIUM SENSITIZER | ORION CORP (FI) | 2004-03-10 | — | — | EP | disclosed |
| US-RE38102-E1 | Use of a pyridazinone derivative | ORION CORPORATION (FI) | 2003-04-29 | — | — | US | disclosed |
| US-RE38102-E1 | Use of a pyridazinone derivative | ORION CORPORATION (FI) | 2003-04-29 | — | — | US | disclosed |
| WO-2003004035-A1 | NEW USE OF A PYRIDAZINONE DERIVATIVE | ORION CORPORATION (FI) | 2003-01-16 | — | — | WO | disclosed |
| EP-1087769-A1 | USE OF A PYRIDAZINONE DERATIVE | ORION CORPORATION (FI) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999066932-A1 | NEW USE OF A PYRIDAZINONE DERIVATIVE | ORION CORPORATION (FI) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999056134-A1 | A METHOD FOR MONITORING THE TOLERABILITY OF LEVOSIMENDAN ADMINISTRATION | ORION CORPORATION (FI) | 1999-11-04 | — | — | WO | disclosed |
| US-5905078-A | TREATMENT OF NEUROHORMONAL IMBALANCE | ORION CORPORATION (FI) | 1999-05-18 | — | — | US | disclosed |
| US-5905078-A | TREATMENT OF NEUROHORMONAL IMBALANCE | ORION CORPORATION (FI) | 1999-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330463-A1 | Pharmaceutical Compositions for Subcutaneous Administration of Levosimendan | TNNC1, CS, MEF2D | PDE3B 222/4885PDE3A 319/4885KDM4E 1585/4885 |
| US-20210236504-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | CREB1, CREBBP, SLFN12 | PDE3B 11/4885PDE3A 7/4885KDM4E 2202/4885 |
| US-20220370445-A1 | METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE | CHRM5, KCNN4, TNNI3 | PDE3B 447/4885PDE3A 374/4885KDM4E 2320/4885 |
| US-10966986-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | SLFN12, CREB1, CREBBP | PDE3B 10/4885PDE3A 6/4885KDM4E 2614/4885 |
| US-20220071995-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | SMPD3, SMPD1, SMPD2 | PDE3B 21/4885PDE3A 15/4885KDM4E 2875/4885 |
| US-11213524-B2 | Pharmaceutical compositions for subcutaneous administration of levosimendan | TNNC1, CS, MEF2D | PDE3B 222/4885PDE3A 319/4885KDM4E 1585/4885 |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, RB1, CDK4 | PDE3B 2667/4885PDE3A 2661/4885KDM4E 1947/4885 |
| US-20060166994-A1 | Method for treating renal failure | TNNI3, ATP6V1B1, REN | PDE3B 65/4885PDE3A 66/4885KDM4E 3522/4885 |
| US-12616694-B2 | Pharmaceutical compositions for subcutaneous administration of levosimendan | MEF2D, TNNC1, CFD | PDE3B 130/4885PDE3A 287/4885KDM4E 1352/4885 |
| US-20220096470-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION OF LEVOSIMENDAN | TNNC1, CS, MEF2D | PDE3B 222/4885PDE3A 319/4885KDM4E 1585/4885 |
| US-11207320-B2 | Compositions and methods for cancer expressing PDE3A or SLFN12 | SMPD3, SMPD1, SMPD2 | PDE3B 21/4885PDE3A 15/4885KDM4E 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.